Cardiovascular adverse events following treatment for non-Hodgkin lymphoma - Authors' reply

Marijke Linschoten; Janine Am Kamphuis; Folkert W Asselbergs

doi:10.1016/S2352-3026(20)30228-3

Cardiovascular adverse events following treatment for non-Hodgkin lymphoma - Authors' reply

Marijke Linschoten, Janine Am Kamphuis, Folkert W Asselbergs

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	e557-e558
Journal	Lancet haematology
Volume	7
Issue number	8
DOIs	https://doi.org/10.1016/S2352-3026(20)30228-3
Publication status	Published - Aug 2020

Keywords

Cyclophosphamide
Doxorubicin
Humans
Lymphoma, Non-Hodgkin
Prednisone
Rituximab
Vincristine

Access to Document

10.1016/S2352-3026(20)30228-3

Cite this

@article{850b2b39005b4351a563ec47aeb2aa7a,

title = "Cardiovascular adverse events following treatment for non-Hodgkin lymphoma - Authors' reply",

keywords = "Cyclophosphamide, Doxorubicin, Humans, Lymphoma, Non-Hodgkin, Prednisone, Rituximab, Vincristine",

author = "Marijke Linschoten and Kamphuis, {Janine Am} and Asselbergs, {Folkert W}",

note = "Funding Information: ML is supported by the Alexandre Suerman Stipend of the University Medical Centre Utrecht, outside the submitted work. FWA is supported by University College London Hospital's National Institute for Health Research and Biomedical Research, and CardioVasculair Onderzoek Nederland 2015–12 eDETECT, outside the submitted work. JAMK declares no competing interests.",

year = "2020",

month = aug,

doi = "10.1016/S2352-3026(20)30228-3",

language = "English",

volume = "7",

pages = "e557--e558",

number = "8",

}

TY - JOUR

T1 - Cardiovascular adverse events following treatment for non-Hodgkin lymphoma - Authors' reply

AU - Linschoten, Marijke

AU - Kamphuis, Janine Am

AU - Asselbergs, Folkert W

N1 - Funding Information: ML is supported by the Alexandre Suerman Stipend of the University Medical Centre Utrecht, outside the submitted work. FWA is supported by University College London Hospital's National Institute for Health Research and Biomedical Research, and CardioVasculair Onderzoek Nederland 2015–12 eDETECT, outside the submitted work. JAMK declares no competing interests.

PY - 2020/8

Y1 - 2020/8

KW - Cyclophosphamide

KW - Doxorubicin

KW - Humans

KW - Lymphoma, Non-Hodgkin

KW - Prednisone

KW - Rituximab

KW - Vincristine

U2 - 10.1016/S2352-3026(20)30228-3

DO - 10.1016/S2352-3026(20)30228-3

M3 - Article

C2 - 32735830

SN - 2352-3026

VL - 7

SP - e557-e558

JO - Lancet haematology

JF - Lancet haematology

IS - 8

ER -